

# Subject Index

## A

- Actin, 17
- Actinobacillus pleuropneumoniae*, 249-250
- Adherence assay, 184
- Adherence to human neutrophils, 188-189
- Adhesin gene of *Mycoplasma pirum* in AIDS patients, 279-282
- Adhesion molecules, 170
- Adjuvant cholera toxin, 219
- Adult respiratory distress syndrome, 140
- Agammaglobulinemia in children with measles virus, 114
- Aged animals, mucosal immunity in, 151-153
- Aging and depressed immune response, 151
- AIDS, 40, 279-282
- AIDS-like CD4<sup>+</sup> T-cell lymphopenia, 79
- Alloxan and diabetes mellitus, 310-311
- Alpha/beta T cells in immunity, 53-67
- Alveolar macrophages, 141
- Amphotericin B, 93-104
- Anaerobes, 183
- Anaerobic growth, 187-188, 189
  - and CMP-NANA, 185-186
- Annexins, translocation of, 326-328
- Antibody
  - in autoimmune thyroid disease, 345-347
  - levels and immunogenicity, 108
  - responses, systemic, 222-224
- Antibody-secreting cells, 220
- Antigen, multiple banded, 299-301
- Antigen-specific T-cell proliferation, 225
- Antigenic variation, viral, 37-41
- Antidiotype antibodies as polysaccharide vaccines, 209-215
- Apoptosis, macrophage, and *S. flexneri*, 199-201
- Arenaviruses*, 109
- Autoimmune thyroid disease, 345-347
- Autoimmunity, 126-127

## B

- Bacteremia, 212, 213, 214
  - streptococcal, 238
- Bacterial adherence, 249-250
  - and IL-6 and IL-8 secretion, 169
  - and mucosal cytokine production, 162-177
- Bacterial adhesins, 162-164
- Bacterial infections and IL-8 expression, 140-141
- Bacterial killing, 283-285
- Bacterial lectins, 162-164
- Bactericidal action of serum, 192
- BALB/c mice, 210-212
- 4-1BB, 119

- Bcg, the natural resistance gene, 313-314
- Bladder infection, protection against, by stress, 302-303
- Bone marrow transplantation, 76
  - autologous, 238
- Borrelia burgdorferi*, inactivated, immunization with, 364-366
- Brazilian purpuric fever, 260-262, 269-272, 297-298
- Bronchoalveolar lavage, 141
- Brucella*, intracellular behavior of, 276-278
- Butyrate, 246-248

## C

- Candidiasis, 75
- Capsular polysaccharide, 209, 315-317
- Cardiac defect, 76
- CD18, 202
- CD27, 119
- CD3<sup>+</sup> T cells, 76-77
- CD4<sup>+</sup> helper cells, 318-321
- CD4<sup>+</sup> T cells, 225
  - and *B. burgdorferi* infection, 364-366
- CD4<sup>+</sup> Th cell subset, 84
- CD4<sup>+</sup> Th1 and Th2 cells, 84
- CD40, 119
- CD8<sup>+</sup> cytotoxic cells, 318-321
- Cell biology of infection, 15-22
- Cell-mediated immune response in hepatic injury, 318-321
- Cells (*see specific cell*)
- Chemoattractants, 170
- Chemotactic cytokines, 136-137
- Chemotactic factors, 135-137
- Chemotherapy, infections after, 235-241
- Chick embryo model of *Neisseria meningitidis*, 266-268
- Children, Brazilian purpuric fever in, 260-262, 269-272, 297-298
- Chlamydia trachomatis*, 304-305
- Chlamydia trachomatis* serovar L2 in HeLa and McCoy cells, 326-328
- Chlamydial persistence, 304-305
- Cholera toxin, adjuvant, 219
- Class II MHC and foreign peptide binding, 338-341
- Class II MHC antigens, 275
- CMP-NANA (cytidine monophospho-N-acetyl neuraminic acid), 183, 187, 188, 190-194
- Coevolution of TNF receptors and ligands, 121-123
- Colon in shigellosis, 197
- Complement C1q and attachment of gonococcal cells to uterus, 292

- Computerized image analysis, 287
- Conotruncal cardiac defects, 76
- CTL epitope map of lymphocytic choriomeningitis virus, 110
- CTL epitopes, 110-111
- Cytokine balance, 74
- Cytokine networks, 136-137
- Cytokine patterns in leprosy, 42-49
- Cytokine production
  - and acute endotoxemia, 336-337
  - in macrophages, 313-314
  - mucosal, and bacterial adherence, 162-177
- Cytokine response in *Neisseria gonorrhoeae* infection, 322-324
- Cytokines, 42-49, 67, 73, 74, 85, 128, 136-137, 162, 166-169, 176-177, 200-201, 239-240, 313-314, 336-337
- and hepatitis A virus, 318-321
- combined, 239-240
- detection of, 43-44

- D**
  - Death domain, 121
  - Dehydroepiandrosterone (DHEA), 145
  - Dense granule proteins, 2, 4
  - Diabetes mellitus, alloxan-induced, 310-311
  - Diarrhea, 197
  - DiGeorge syndrome, 76-78
  - Digital confocal microscopy, 287
  - 1,25 Dihydroxyvitamin D<sub>3</sub> (1,25(OH)<sub>2</sub>D<sub>3</sub>), 147
  - Disseminated gonococcal infection (DGI), 8, 10-11
  - DNA supercoiling, 187-188
  - Duplication of TNF receptor gene, 122
  - Dysentery, 197

## **E** - ELISPOT, 225-227

- Endotoxemia
  - and cytokine production, 336-337
  - and nitric oxide, 329-330
- Enrichment protocol, 29
- Enrichment scheme, limitation of, 33-34
- Epithelial cells, 201
- Epithelium
  - Escherichia coli* in, 286-289
  - in shigellosis, 197
- Escape into cytoplasm, 33
- Escherichia coli*
  - and short chain organic acid butyrate, 246-248
  - enterohemorrhagic, 310-311
  - fimbriae in pregnancy with pyelonephritis, 290
  - in fallopian tube epithelium, 286-289
  - killing of, by polymorphonucleocytes, 283-285
  - recolonization with, 243-245
  - uropathogenic, 162-177

- Evolution, hormones in, 118

- F**
  - fallopian tube epithelium, 286-289
  - Fas, 119
  - Fast neutron irradiated cells and *Salmonella typhi*, 348-349
  - Fimbriae, 162-164
  - Flow microfluorimetry, 273-275
  - Fungal infections and amphotericin B, 93-104

- G**
  - GalE* gene, 252-254
  - Gamma/delta T cells in immunity, 53-67
  - Gamma interferon, 84
    - in chlamydial growth, 304-305
  - Generalized lymphoproliferative disease (*Gld*), 124-126
  - Genes (*see also specific gene*)
    - function regulated by steroid hormones *in vivo*, 159
    - in *Mycobacterium tuberculosis*, 263-265
    - in resistance of mycobacteria to killing by macrophages, 26
    - virulence-related, 295-296
  - Gestational pyelonephritis, *E. coli* fimbrial types in, 290-291
  - Globoseries of glycolipids, 164-165
  - Glycolipids, 164-165
  - Gonococcal cells, attachment of, to uterus, 292-293
  - Gonorrhea, 7-14, 182-185, 286-289, 292, 322-324
    - transmission of, 9
  - Granulocyte-macrophage colony-stimulating factor, 236-238, 240
  - Growth factors, hematopoietic, for infections, 235-241

- H**
  - Haemophilus influenzae* biogroup aegyptius, 269-272, 297-298
  - Haemophilus influenzae*, 169 mutation of, 255-256
  - HeLa cells, 326-328
  - Heat shock proteins, 246
  - Hematopoietic growth factors for infections, 235-241
  - Hemolysin, 15
  - Hepatic injury, nitric oxide in, 329-330
  - Hepatitis A virus, 318-321
  - Hepatitis B, chronic, 74
  - HIV-1, 39-40
  - HMEC-1 tissue culture cells, 269-272
  - Hormonal immunomodulation, 147-150
  - Hormones in evolution, 118
  - Host defenses and pathogenic *Neisseria*, 182-195
  - Hypoparathyroidism, 76

- I**  
I69 mutation of *Haemophilus influenzae*, 255-256  
iC3b, 7  
ICAM, kinetics of, 170-176  
icsA genes, 198  
Idiotopes, 209  
Immune deficiency disorders of, 74-76  
thymic factors in, 71-80  
Immunity induced by porins from *S. typhi*, 350-352  
innate and acquired, 53-67, 84-90  
protective, 215  
using minigenes, 107-115  
Immunization (see also Vaccines) against *S. typhi*, 348-349  
oral, with tetanus toxoid, 219-232  
Immunoaberrant patients, 307-309  
Immunoglobulin A, 220-221  
Immunosuppressive virus and persistent infection, 113-114  
Inappropriate vaccination, 107  
Increased resistance to killing, 32-33  
Infection, 76  
after chemotherapy, 235-241  
and cytokine response, 322-324  
bladder, 302-303  
by hepatitis A virus, 318-321  
cell biology of, 15-22  
fatal, in children, 260-262, 269-272, 297-298  
fungal, 93-104  
interleukin-8 in, 134-141  
mycobacterial, 313-314  
resistance to, and T cells, 66-67  
*S. viridans* in, in Mauritius, 332-334  
with *B. burgdorferi*, 364-366  
Infectious diseases, 37 (see also specific diseases)  
vaccination for, 158-159  
Inflammation, 134, 197  
Inflammatory bowel disease, recolonization therapy in, 243-245  
Inflammatory cytokine response in infection, 322-324  
Inflammatory cytokines, 200  
Influenza-specific antibody-secreting cells, 152  
Influenza-specific secretory immunoglobulins, 151  
Inhibition of phagosome-lysosome fusion, 33  
Innate immune response, 85  
Integrins, 201  
Interleukin-1, 66-67, 166, 200  
Interleukin-1 alpha, 134  
Interleukin-1 beta, 134, 322-324  
Interleukin-2, 74  
Interleukin-3, 236, 238, 240  
and GM-CSF, 239-240  
Interleukin-4, 139, 226  
Interleukin-4+ lymphocytes in hepatitis A virus, 318-321  
Interleukin-5, 227  
Interleukin-6, 166, 169, 200, 236, 322-324  
production in *Legionella* infection, 342-343  
Interleukin-6+ lymphocytes in hepatitis A virus, 318-321  
Interleukin-7, 46  
Interleukin-8, 169, 322-324  
in infectious process, 134-141  
Interleukin-10, 139  
Interleukin-12, 46-66-67  
Interleukins, 73  
Intracellular pathogens, 15, 27  
Intracellular survival, 27, 276-278  
Intralipid and amphotericin B, 101-103  
Invariant chain dissociation from class II MHC, 338-341  
Invasion genes, 28  
Invasiveness of *Shigella flexneri*, 197-198  
ipa genes, 198  
Iron dextran, 210-211  
**J**  
J774 cells, 20, 273-275  
Jarisch-Herxheimer reaction, 1  
**K**  
Kinetics of survival in macrophages, 29  
*Klebsiella pneumoniae*, 315-317  
Kupffer cells, 137  
**L**  
L-AmpB, renal cytotoxic effects of, 93-94, 96  
*Legionella* infection, 342-343  
*Legionella pneumophila* infected macrophages and nitric oxide, 342  
*Leishmania major*, 84-90  
Leishmaniasis, 88-90  
Lentiviruses, 39-40  
Leprosy, 26-34, 42-49  
cytokine patterns in, 42-49  
Leukotoxin nonproducing mutant of *P. haemolytica*, 283-285  
Lipooligosaccharides, 8, 10, 186, 189-190  
gonococcal, 183  
phenotypes, 192-194  
Lipopolysaccharides, 168, 200, 250, 252-254  
Lipoproteins, serum, and amphotericin B, 94  
*Listeria*, 63  
intracellular behavior of, 276-278  
*Listeria monocytogenes*, 21-22, 127  
fluorescent labeling of, 273-275  
infection, cell biology of, 15-22

- LLC PK1 renal cells and amphotericin B, 98-101
- LT-alpha and LT-beta, 119
- Lung macrophages and endotoxin, 336-337
- Lyme disease, 364-366
- Lymphocytic choriomeningitis virus, 109
- Lymphoid malignancies, 238
- Lymphoid solitary nodules, 201
- Lymphokines, 145
- Lymphoma, 239
- Lymphopenia, 79
- Lymphoproliferation (*Lpr*), 124
- Lymphotoxin, 119
- M** cells and mucosal immune response, 199
- Mac 1, 202
- Macrophages, 199-201
- cytokine and nitric oxide production by, 336-337
- L. pneumophila* in, in infection, 342-343
- resistance of mycobacteria to killing by, 26-34
- Mauritius, *S. viridans* infections in, 332-334
- McCoy cells, 326-328
- Measles vaccination, 107
- Melioidosis, 140
- Methylamine, 9
- MHC link among ligand family members, 121
- Midline defects, 76
- Minigene, protective immunity using, 107-115
- MØ cell-associated TNF $\alpha$ , 307-309
- Monoclonal immunoglobulin A, 356-357
- Monocyte-derived neutrophil chemotactic factor (MDNCF), 135
- Mononuclear cell infiltration, 135
- mRNA subtractive hybridization, 269-272
- Mucosal antibody responses to tetanus toxoid and cholera toxin, 220
- Mucosal cytokine production and bacterial adherence, 162-177
- Mucosal cytokines, uroepithelial cells as source of, 168-169
- Mucosal immune response, 356-357
- and M cells, 199
- Mucosal immunity, induced, 353-355
- Mucosal infections, 162
- Mucosal secretions, secretory antibodies in, 144-145
- Mucosal surfaces, acquiring pathogens through, 218
- Mucus, 249-250
- Mutations distinguish TNF-alpha and LT-alpha, 122
- mviA*, 295-296
- mxi* genes, 198
- Mycobacteria, 313-314
- Mycobacteria killing by macrophages, 26-34
- Mycobacterium leprae*, 26-34, 42-49
- Mycobacterium leprae* cosmid library, 30-31
- Mycobacterium leprae* plasmid library, 31-32
- Mycobacterium tuberculosis*, 26-34
- Mycobacterium tuberculosis* strain H37 Rv, 263-265
- Mycoplasma pirum*, adhesin gene of, 279-282
- Mycoplasmas as cofactors in AIDS, 279-282
- N**-end rule, 22
- N*-monomethyl-L-arginine as nitric oxide inhibitor, 342-343
- Natural killer cells, 74, 87-88
- Natural resistance gene, *Bcg*, 313-314
- Neisseria gonorrhoeae*, 182-195, 322-324
- infection of uterine endometrium by, 292
- opacity-associated proteins, 286-289
- serum resistance of, 7-14
- Neisseria meningitidis*, 252-254, 257-259, 266-268
- Neisseria meningitidis* serogroup C polysaccharide, 210-215
- Neisserial major outer membrane proteins, 367-369
- Neisserial porins, 367-369
- Nephrotoxicity of amphotericin B, 93-104
- Neutralizing antibody, 213
- Neutrophil granules, 184
- Neutrophil influx, 169-176
- Neutrophil lysosomal enzymes, 191
- Neutrophil migration, 170-171
- Neutrophil-dependent chemokine expression, 137-139
- New generation vaccines, 114
- Nitric oxide
- and acute endotoxemia, 336-337
- in hepatic injury after acute endotoxemia, 329-330
- in *Legionella pneumophila* infected macrophages, 342
- Nonobese diabetic mice, 126-127
- Nucleoprotein particle-amplified antigen, 353-355
- NZB mice, 126-127
- NZW mice, 126-127
- O** pacity-associated (Opa) proteins, 183, 190, 191, 286
- Opsonization of *K. pneumoniae*, 315-317
- Oral delivery systems, 217-232
- microspheres as, for tetanus toxoid, 230
- Oral vaccine models, 217-232
- Organelle association with parasitophorous vacuole membrane, 3
- Oxygen-dependent killing mechanisms, 27
- Oxygen-independent killing mechanisms, 27

- P** fimbriae, 162-164  
Paracrine and autocrine interactions, 138  
Parasitophorous vacuole membrane, 1-4  
Parathyroid dysfunction, 75  
*Pasteurella haemolytica*, 283-285  
Pathogens (*see specific pathogen*)  
Pathogen-macrophage interaction, 26  
Pathogens acquired through mucosal surfaces, 218  
Pelvic inflammatory disease, 9  
Pelvic tissue, attachment of gonococcal cells to, 292-293  
Peptide binding and invariant chain dissociation, 338-341  
Perfringolysin O, 19  
Permeability of parasitophorous vacuole membrane, 3  
Peyer's patch, CD4<sup>+</sup> T cells isolated from, 225  
Peyer's patches, 201  
PGE<sub>2</sub> in MØ supernatants, 307-309  
PGE<sub>2</sub> resistance to cell-associated TNF alpha, 307-309  
Phagocytic killing, 188, 190, 193  
Phagocytic killing assay, 184  
Phagocytosis, 27, 33  
    and *K. pneumoniae* serotypes, 315-317  
Pneumococcal surface protein A, 361-362  
Pneumonia in cattle, 283-285  
Point mutation, 38  
Poly D,L-lactide-co-glycolide microspheres, 228  
Polymerase chain reaction, 44  
Polymorphonuclear leukocytes, 135  
Polymorphonucleocytes  
    and *Pasteurella haemolytica*, 283-285  
    and *S. flexneri* invasion, 201-202  
Polysaccharides, 209  
    as test antigen, 367-369  
Porins from *S. typhi* in inducing immunity, 350-352  
Pregnancy, pyelonephritis in, 290-291  
Prethymic precursor T cells, 72  
Profilin, 17  
Proinflammatory cytokines, 176-177  
Prolactin receptor, 73  
Protective epitopes of pneumococcal surface protein A, 361-362  
Protective immunity, 224  
Proteins (*see also specific protein*), 2, 4, 8, 10-11, 127, 138, 162-164  
Pyelonephritis in pregnancy, 290-291  
**R**eceptor/ligand couples, 121  
Recolonization therapy with *E. coli*, 243-245  
Recombinant cytokine-binding proteins, 127  
Recombinant *S. typhimurium*, oral immunization with, 230  
Recombinant viral vaccines, 108  
Reduction modifiable protein (Rmp), 8, 10-11  
Reflorastation in inflammatory bowel disease, 243-245  
Repressor proteins, 138  
Respiratory syncytial virus infection, 79  
Retroviruses, 39-40  
Rhoptry proteins, 2, 4  
Ribosomes in vaccine delivery system, 353-355  
Route of administration in immunization, 227  
**S** fimbriae, 163  
Salicylate in *K. pneumoniae*, 315-317  
*Salmonella typhi*  
    and fast neutron irradiated cells, 348-349  
    in protective immunity, 350-352  
*Salmonella typhimurium*, 295-296  
    fluorescent labeling of, 273-275  
Secretory antibodies in mucosal secretions, 144-145  
Secretory IgA (S-IgA), 218  
Sequence-based analysis of evolution of ligand and receptor molecules, 123  
Serum bactericidal assay, 184  
Serum killing, 182, 185  
Serum lipoproteins and amphotericin B, 94  
Serum resistance, 186  
Shedding, uroepithelial, in bladder infection, 302-303  
*Shigella flexneri*  
    2a, 359-360  
    lipopolysaccharide, 356-357  
    tissue invasion by, 197-205  
*Shigella* vaccine, 353-355  
Shigellosis, 197-205  
    and intracellular movement, 202-204  
    conjugate vaccines for, 359-360  
Shock, 123  
Sialylated gonococci, 192  
Sialyltransferase (STase), 183, 187  
*spa* genes, 198  
Spleen, CD4<sup>+</sup> T cells isolated from, 225  
*Staphylococcus aureus* killing by polymorphonucleocytes, 283-285  
Stem cells, 235  
Steroid hormones in regulating gene function *in vivo*, 159  
Streptococcal bacteremia, 238  
*Streptococcus pneumoniae*, 75  
    respiratory infections with, 361-362  
*Streptococcus viridans* in infections in Mauritius, 332-334

- Stress in protecting against bladder infection, 302-303
- String-of-beads vaccine, 112-113
- Supercoiling of gonococcal DNA and anaerobic growth, 187-188
- Synthetic peptide vaccines, 108
- T** cells
- and resistance to infection, 66-67
  - in innate and acquired immunity, 53-67
  - in leprosy lesions, 42
- T helper cell responses in systemically immunized mice, 227-228
- T-84 cell line, 201
- T-cell cytokines, 176-177
- T-cell function and steroid hormones, 146-147
- T-cell lymphokine production, 144-159
- T-cell presented peptides, binding of, 338-341
- T-cell proliferation, antigen-specific, 225
- T-cell receptors, 53
- in leprosy, 47-48
- T-dependent antigen, 209
- T-helper type 1 or 2, 74
- T-independent antigens, 209
- TCR  $\alpha\beta$  double-negative cells, 48
- TCR  $\gamma\delta$  cells, 48
- Tetanus toxoid, 217-232
- TGF beta downregulation, 307-309
- Thymic factors in immune deficiency, 71-80
- Thymic hypoplasia, 75
- Thymosin alpha 1, 73
- Thymosin fraction 5, 73
- Thymulin, 73
- Thymus and immunity, 71-80
- Tissue culture invasion assays for *N. meningitidis*, 257-259
- Tissue culture model for studying Brazilian purpuric fever, 260
- Tissue invasion by *Shigella flexneri*, 197-205
- TNF alpha production, 307-309
- TNF ligand and receptor families, origins of, 118-128
- TNF/NGF family of receptors, 121
- Toxoplasma gondii*, 1-4

- Transcriptional levels, 139
- Transmigration of polymorphonucleocytes, 201
- Trypsin, 7
- Tryptophan in gamma interferon-mediated chlamydial persistence, 304
- Tuberculosis, pathogenesis of, 263-265
- Tumor necrosis factor, 200-201
- Tumor necrosis factor alpha, 118, 134, 166, 322-324

- U**-937, 276-278
- Ureaplasma urealyticum*, 299-301
- Urethritis, 9
- Urinary tract infections, 162
- Uroepithelial cells, 176-177
- Uroepithelial shedding in bladder infection, 302-303

- V**accination
- inappropriate, 107
  - measles, 107
  - parenteral, with weak antigen, 353-355
- Vaccine adjuvants with natural regulators of T-cell lymphokine production *in vivo*, 144-159
- Vaccines
- neisserial major outer membrane proteins in, 367-369
  - oral, 217-232
  - polysaccharide, 209-215
  - string-of-beads, 112-113
  - synthetic peptide, 108
- Viral antigenic variation, 37-41
- Viral infections, 123-124
- Virulence, 297-298
- Virulence-related gene regulation in *S. typhimurium*, 295-296
- Virus, hepatitis A, 318-321
- Viruses, 37-41, 74, 79, 108, 109, 123-124, 318-321 (*see also specific virus*)
- survival strategies of, 38-39

- Y**ersinia enterocolitica, 345-347
- Z**inc, 73

## Index of Contributors

**A**brams, R. S., 243-245

Ades, E. A., xiii, 260-262

Agace, W., 162-181

Amano, F., 313-314

Apicella, M. A., 209-216

Araneo, B. A., 144-161

Aronson, M., 302-303

Asher, L. V. S., 318-321

**B**ahraoui, E., 279-282

Barteneva, N. S., 345-347

Beatty, W. L., 304-306

Beckers, C. J. M., 1-6

Bélanger, M., 249-251

Belanger, T. A., 304-306

Benjamin, W. H., Jr., 295-296

Bermudes, D., 1-6

Beutler, B., 118-133

Binn, L. N., 318-321

Birkness, K. A., 257-259, 266-268

Blake, M. S., 7-14

Blanchard, A., 279-282, 299-301

Briles, D. E., 361-363

Bryla, D., 359-360

Bunning, V. K., 273-275

Byrne, G. I., 304-306

**C**ampagnari, A. A., 209-216

Canarelli, B. S., 279-282

Cao, Z., 299-301

Caron, E., 276-278

Cassell, G. H., 299-301

Cavaillon, J. M., 356-358

Chatfield, S. N., 217-234

Chretien, P. B., 71-83

Cross, A. S., 315-317, 322-325

Cunha, B. A., 315-317

Cunningham-Rundles, S., 71-83

**D**aibata, M., 338-341

Dalal, E., 302-303

Daynes, R. A., 144-161

Deal, C. D., 322-325

Desai, A. A., 304-306

Dima, F. V., 310-312, 348-349

Dima, S. V., 310-312, 348-349

Domenico, P., 315-317

Dubremetz, J. F., 1-6

Dubreuil, D., 249-251

**E**gorova, T. P., 353-355

Ernst, J. D., 326-328

Espejo, R., 338-341

Evstafieva, A. G., 345-347

Ewing, E. P., Jr., 266-268

**F**elser, J. M., 235-242

Ferris, S., 279-282

Fischer, A., 364-366

Flores, G., 292-294

Folks, T. M., 37-41

Frangipane, J. V., 182-196

Frey, A. B., 364-366

Friedman, H., 342-344

Froshauer, S., 283-285

**G**eorge, V. G., 257-259, 260-262

Giardina, P., 209-216

Gilley, R. M., 217-234

Glass, J. I., 299-301

González, C. R., 350-352

Gorby, G., 286-289

Gordon, J. A., 283-285

Gorelov, V. N., 345-347

Gotschlich, E. C., 7-14

Guilfoyle, D. E., 246-248

Guirguis, S., 71-83

Gulati, S., 7-14

**H**arari, O., 302-303

Harbison, M., 71-83

Harrigan, M. B., 283-285

Hart, A., 290-291

Heck, D. E., 329-331

Hedges, S., 162-181

Hirshfield, I. N., 246-248

Hudson, M. E., 217-234

Huerre, M., 356-358

Humphreys, R. E., 338-341

Hwang, S. M., 329-331

**I**sibasi, A., 350-352

Ivanov, D., 348-349

**J**ackson, R. J., 217-234

Jacques, M., 249-251

Jani, D. B., 7-14

Jennings, M. P., 252-254

Jhaver, K., 307-309

Joiner, K. A., 1-6

Jones, S., 15-25

**K**aufmann, M., 356-358

Kaul, A., 292-294

Kempf, M. C., 299-301

Kihlström, E., 326-328

Kikuta-Oshima, L. C., 263-265  
 King, C. H., 263-265  
 Kiyono, H., 217-234  
 Klein, T. W., 342-344  
 Kodys, K., 307-309  
 Köhler, S., 276-278  
 Krachenbuhl, J. P., 356-358  
 Kumar, D., 292-294  
 Kumate, J., 350-352  
 Kunkel, S. L., 134-143  
 Kuschner, R. A., 322-325

**L**aky, D., 310-312  
 Laskin, D. L., 329-331, 336-337  
 Laskin, J. D., 329-331  
 Levenson, V. J., 353-355  
 Liautard, J.-P., 276-278  
 Lindstedt, R., 162-181  
 Liu, J., 182-196  
 Long, E. G., 260-262  
 Lopez-Berestein, G., 93-106  
 López-Macias, C., 350-352  
 Lukacs, N. W., 134-143

**M**agnusson, K.-E., 326-328  
 Majeed, M., 326-328  
 Martens, M., 290-291, 292-294  
 Martín, N., 350-352  
 Maskell, D. J., 252-254, 255-256  
 McCann, M. L., 243-245  
 McDaniel, L. S., 361-363  
 McGhee, J. R., 217-234  
 McQuillen, D. P., 7-14  
 Medalia, O., 302-303  
 Michetti, P., 356-358  
 Miller-Graziano, C. L., 307-309  
 Modlin, R. L., 42-52  
 Montagnier, L., 279-282  
 Morrison, R. P., 304-306  
 Morse, S. A., 371-374  
 Moxon, E. R., 252-254, 255-256  
 Mundayoor, S., 26-36  
 Murphy, F. A., 371-374

**N**akamura, R. M., 313-314  
 Nelson, R. P., Jr., 243-245  
 Nowicki, B., 290-291, 292-294  
 Nowicki, S., 290-291, 292-294

**O**rtiz-Navarrete, V., 350-352  
 Ossorio, P. N., 1-6

**P**aniagua, J., 350-352  
 Pearce, K. M., 53-70  
 Perdomo, J. J., 197-208  
 Phalipon, A., 356-358  
 Pine, L., 266-268

Polotsky, V. Y., 359-360  
 Polotsky, Y. E., 318-321  
 Poolman, J. T., 252-254  
 Portnoy, D. A., 15-25  
 Preston, A., 255-256

**Q**uinn, F. D., 257-259, 260-262, 263-265,  
 266-268, 269-272

**R**ai, J., 332-335  
 Ralph, B. A., 361-363  
 Ramírez, G., 350-352  
 Ramsey, K. H., 322-325  
 Rao, T. D., 364-366  
 Raybourne, R. B., 273-275  
 Rest, R. F., 182-196, 286-289  
 Reyes, V. E., 338-341  
 Ribot, E., 257-259  
 Rice, P. A., 7-14  
 Ricketts, A. P., 283-285  
 Robbins, J. B., 359-360  
 Rodriguez-del Valle, M., 329-331  
 Rojo, M. P., 350-352  
 Rubin, L. G., 297-298

**S**alo, R. J., 315-317  
 Sánchez, J., 350-352  
 Sansonetti, P. J., 197-208, 356-358  
 Scharton, T., 84-92  
 Schneerson, R., 359-360  
 Schneider, H., 322-325  
 Schwab, J. C., 1-6  
 Scott, P., 84-92  
 Shinnick, T. M., 26-36, 263-265  
 Sieling, P. A., 42-52  
 Simon, D., 182-196, 286-289  
 Skeen, M. J., 53-70  
 Staats, H. F., 217-234  
 Stendahl, O., 326-328  
 Stephens, D. S., 257-259, 266-268  
 Strieter, R. M., 134-143  
 Svanborg, C., 162-181  
 Svensson, M. L., 162-181  
 Swords, W. E., 295-296

**T**akahashi, I., 217-234  
 Talukdar, R., 182-196  
 Teng, L.-J., 299-301  
 Tham, T. N., 279-282  
 Trofa, A. F., 322-325

**U**tt, E. A., 260-262, 269-272

**V**alacer, D., 71-83  
 Van Der Ley, P., 252-254  
 Van Huffel, C., 118-133  
 Vassell, R. A., 318-321



**W**asan, K. M., 93-106  
 Watson, H. L., 299-301  
 Wenzel, B. E., 345-347  
 Westerink, M. A. J., 209-216  
 Wetzler, L. M., 7-14, 367-370  
 Weyant, R. S., 260-262  
 White, E. H., 260-262, 266-268  
 Whitton, J. L., 107-117  
 Wilks, K. E., 252-254

Wizemann, T. M., 336-337  
 Worley, M. J., 260-262

**X**u-Amano, J., 217-234

**Y**amamoto, Y., 342-344

**Z**heng, X., 299-301

Ziegler, H. K., 53-70

Zychlinsky, A., 197-208